Metformin: A review on therapeutic role in diabetes mellitus and cardiovascular disorder

International Journal of Pharmaceutical Sciences Review and Research

Volumn 10, Issue 1, 2011, Pages 147-151

  Wadher, K J ^a   Kalsait, R P ^a   Kakde, R B ^b   Umekar, M J ^a  

^a New Kamptee   (India)

^b Mahatma Jyotiba Fule Shaikshanik Parisar University Campus   (India)

Author keywords

Diabetes; Hyperglycemia; Metformin; Polycystic ovary syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN; PHENFORMIN;

ARTICLE; BLOATING; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FOOD INTAKE; GLYCEMIC CONTROL; HUMAN; IMMOBILIZATION; INDIA; LACTIC ACIDOSIS; MALABSORPTION; MENTAL STRESS; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSICAL STRESS; RISK ASSESSMENT; RISK FACTOR; SEDENTARY LIFESTYLE; STOMACH PAIN; URBANIZATION; VITAMIN B12 MALABSORPTION; WEIGHT REDUCTION;

EID: 84858275739     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
2. Mayor S. Diabetes affects nearly 6% of the world's adults. BMJ. 2006; 333:1191.
3. Bloomgarden ZT. Diabetes complications. Diabetes Care. 2004;27:1506-14.
4. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care. 2008;31:1260-6.
5. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol. 2004; 44:397-405.
6. WHO. Diabetes Programme. Facts and Figures [http://www.who.int/diabetes/facts/en/index.html. Accessed June 5, 2009.
7. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004 May;89(5):2078-84.
8. CDC. 2007 Diabetes Fact Sheet; 2009.
9. Gerich J. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest. 2002;32(3):46-53.
10. ADA. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009;32(S1):S62-7
11. Valiathan MS. The Legacy of Caraka. Hyderabad. Orient Longman 2003; 88-91.
12. Rajeev Gupta and Anoop Misra Review: Type 1 diabetes in India: regional disparities. British Journal of Diabetes and Vascular Disease January 2007 vol 7 no 1, 12-16.
13. Merck A. The Merck Manual of Diagnosis and Therapy. Section 2. Endocrine and Metabolic Disorders. Chapter 13. Disorders of Carbohydrate Metabolism
14. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006; 49:1711-21.
15. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.
16. Krall LP, Camerini-Davalos R. Early clinical evaluation of a new oral non-sulphonylurea hypoglycemic agent. Proc Soc Exp Biol Med 1957;95: 345-7.
17. Ungar G, Freedman L, Shapiro SL. Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med. 1957;95:190-2.
18. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point? Diabetologia. 2005;48:2454-9.
19. Bailey CJ. Metformin: a multitasking medication. Diabetes Vasc Dis Res. 2008;5:156.
20. Papanas N, Maltezos E, Mikhailidis D. Metformin: diamonds are forever. Expert Opin Pharmacother. 2009 Aug 13
21. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988;4:223-9.
22. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-71
23. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in noninsulin-dependent diabetes mellitus. Drugs. 1995;49:721-49.
24. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12:235-46.
25. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348:607-14.
26. Cusi, K., DeFronzo, RA. Metformin: a review of its Metabolic effects. Diabetes Reviews. V6 N2 1998:89-131
27. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediaterelease metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20:565-72.
28. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338-42.
29. Lalau J, Race J. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab. 2000;2:131-7.
30. Chang CT, Chen YC, Fang JT, Huang CC. Metforminassociated lactic acidosis: case reports and literature review. J Nephrol. 2002;15:398-402.
31. Salpeter SR, Greyber E, Pasternak G, Salpeter E. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;1:CD002967
32. Calabrese AT, Coley KC, Da Pos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434-7.
33. Sulkin TV, Bosman D, Krentz A. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925-9
34. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach. Diabetes Care. 2005;28:539-43.
35. Scarpello JHB, Howlett HCS. Metformin monotherapy and clinical uses. Diabetes Vasc Dis Res. 2008; 5:157-67
36. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-67.
37. Charles, M.A., Eschwege, E. Prevention of Type 2 Diabetes: Role of Metformin. Drugs 1999;58 Suppl.1:71-73.
38. Fontbonne A., Charles MA, Juhan-Vague I, et al. The effect of Metformin on the metabolic abnormalities associated with upper body fat distribution. Results of the BIGPRO 1 trial. Diabetes Care 1996; 19:920-6
39. Glueck CJ, Wang P, Kobayashi S, Philips H, Siever-smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-25.
40. Golay A. Metformin and body weight. Int J Obes 2007;32:61-72
41. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
42. Min hae park,sanjay kinra,kirsten j. Ward, billy white, russell m. Viner, metformin for obesity in children and Adolescents: a systematic reviewdiabetes care 32:1743-1745, 2009
43. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-772.
44. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47-53.
45. Pasquali R, Gambineri A, Biscotti D, et al. Effect of longterm treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:2767-2774.